Merck’s Phase 3 Drug MK-7264 (Gefapixant) IF FDA APPROVED Merck’s Phase 3 Drug MK-7264 (Gefapixant) IFENPRODIL WILL GO PHASE 3 !!
The US Food and Drug Administration (FDA) has accepted Merck's New Drug Application (NDA) for gefapixant—an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults.1 mars 2021
Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%